209.93

0.92% 1.9204

Insulet Corporation (PODD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt PODD? Forum Prognose

Schlusskurs vom Vortag:

$208.01

Offen:

$210.81

24-Stunden-Volumen:

400.60K

Relative Volume:

0.42

Marktkapitalisierung:

$14.77B

Einnahmen:

$2.71B

Nettoeinkommen (Verlust:

$247.10M

KGV:

59.97

EPS:

3.5008

Netto-Cashflow:

$349.90M

1W Leistung:

-6.91%

1M Leistung:

-14.88%

6M Leistung:

-32.00%

1J Leistung:

-20.06%

1-Tages-Spanne:

$206.55

$212.92

1-Wochen-Bereich:

$205.11

$227.24

52-Wochen-Spanne:

$205.11

$354.88

Insulet Corporation Stock (PODD) Company Profile

Firmenname

Insulet Corporation

Sektor

Healthcare (1115)

Branche

Medical Devices (143)

Telefon

978-600-7000

Adresse

100 NAGOG PARK, ACTON, MA

Mitarbeiter

5,400

Twitter

@insulet_uk

Nächster Verdiensttermin

2026-02-18

Neueste SEC-Einreichungen

PODD's Discussions on Twitter

Compare PODD vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PODD Insulet Corporation	209.83	14.64B	2.71B	247.10M	349.90M	3.5008
ABT Abbott Laboratories	102.60	177.03B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	328.25	124.89B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	86.75	110.08B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	62.40	93.53B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	80.09	45.84B	6.07B	1.06B	1.34B	1.8063

Insulet Corporation Stock (PODD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-27	Fortgesetzt	TD Cowen	Hold
2026-01-12	Herabstufung	Barclays	Overweight → Equal Weight
2025-12-16	Eingeleitet	Evercore ISI	Outperform
2025-11-19	Hochstufung	UBS	Neutral → Buy
2025-10-21	Fortgesetzt	Stifel	Buy
2025-09-08	Fortgesetzt	Oppenheimer	Outperform
2025-06-16	Eingeleitet	Truist	Buy
2025-05-30	Eingeleitet	Goldman	Buy
2025-05-13	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-04-29	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-03-06	Eingeleitet	RBC Capital Mkts	Outperform
2024-11-06	Eingeleitet	Bernstein	Outperform
2024-05-30	Eingeleitet	Redburn Atlantic	Buy
2024-05-07	Hochstufung	Wolfe Research	Peer Perform → Outperform
2023-12-21	Hochstufung	Robert W. Baird	Neutral → Outperform
2023-12-04	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-10-02	Hochstufung	Jefferies	Hold → Buy
2023-08-21	Hochstufung	Citigroup	Neutral → Buy
2023-08-21	Herabstufung	Robert W. Baird	Outperform → Neutral
2023-05-30	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-01-26	Eingeleitet	Wolfe Research	Peer Perform
2022-11-04	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-18	Eingeleitet	Barclays	Equal Weight
2022-10-12	Eingeleitet	Jefferies	Hold
2022-07-11	Herabstufung	Citigroup	Buy → Neutral
2022-03-02	Fortgesetzt	BofA Securities	Buy
2022-02-03	Hochstufung	BTIG Research	Neutral → Buy
2022-02-02	Hochstufung	UBS	Neutral → Buy
2022-01-31	Hochstufung	Oppenheimer	Perform → Outperform
2021-07-21	Fortgesetzt	Cowen	Outperform
2021-05-25	Eingeleitet	Barclays	Overweight
2021-04-01	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2021-03-19	Hochstufung	Canaccord Genuity	Hold → Buy
2021-01-29	Herabstufung	Piper Sandler	Overweight → Neutral
2020-12-16	Herabstufung	Citigroup	Buy → Neutral
2020-07-28	Eingeleitet	Wells Fargo	Overweight
2020-04-24	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-04-03	Eingeleitet	BofA/Merrill	Neutral
2020-03-31	Herabstufung	Berenberg	Buy → Hold
2020-03-05	Eingeleitet	Citigroup	Buy
2019-12-10	Eingeleitet	CFRA	Sell
2019-10-23	Eingeleitet	Stifel	Hold
2019-10-18	Herabstufung	Canaccord Genuity	Buy → Hold
2019-10-14	Herabstufung	BTIG Research	Buy → Neutral
2019-10-04	Herabstufung	UBS	Buy → Neutral
2019-10-03	Herabstufung	Guggenheim	Buy → Neutral
2019-08-06	Hochstufung	JP Morgan	Neutral → Overweight
2019-06-10	Herabstufung	Northland Capital	Outperform → Market Perform
2019-05-06	Hochstufung	BTIG Research	Neutral → Buy
2018-04-20	Eingeleitet	Berenberg	Buy
2018-02-22	Bestätigt	Barclays	Overweight
2018-01-08	Hochstufung	Raymond James	Mkt Perform → Outperform
2017-11-03	Hochstufung	Canaccord Genuity	Hold → Buy
2017-09-15	Eingeleitet	Barclays	Overweight

Alle ansehen

Insulet Corporation Aktie (PODD) Neueste Nachrichten

11:01 AM

Winners And Losers Of Q4: Insulet (NASDAQ:PODD) Vs The Rest Of The Patient Monitoring Stocks - Yahoo Finance

11:01 AM

07:43 AM

Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD - MarketBeat

07:43 AM

04:32 AM

Insulet (NASDAQ:PODD) Reaches New 12-Month LowTime to Sell? - MarketBeat

04:32 AM

Mar 30, 2026

Insulet Earnings: Stellar Finish to 2025 With Strong Fourth Quarter - Morningstar

Mar 30, 2026

Truist maintains Insulet Corporation (PODD) buy rating despite device correction announcement - MSN

Mar 30, 2026

Insulet Corp. Stock Hits New 52-Week Low at USD 215.26 - Markets Mojo

Mar 30, 2026

Consumer safety roundup: Major recalls affect Einstein Bros., Insulet, Amneal and Falcon Trading - Washington Times

Mar 30, 2026

Insulet Corp (PODD) Shares Down 4.53% on Mar 30 - GuruFocus

Mar 30, 2026

Is Insulet’s (PODD) New CCO Hire a Subtle Reset of Its Global Commercial Strategy? - simplywall.st

Mar 30, 2026

Insulet names Mike Panos as chief commercial officer By Investing.com - Investing.com Canada

Mar 30, 2026

Insulet Corporation Appoints Mike Panos as Executive Vice President and Chief Commercial Officer, Effective March 30, 2026 - marketscreener.com

Mar 30, 2026

SG Americas Securities LLC Purchases 36,570 Shares of Insulet Corporation $PODD - MarketBeat

Mar 30, 2026

Beacon Investment Advisory Services Inc. Cuts Position in Insulet Corporation $PODD - MarketBeat

Mar 30, 2026

Mar 28, 2026

Insulet recalling certain defective Omnipod insulin delivery devices - MSN

Mar 28, 2026

PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm - Business Wire

Mar 28, 2026

Is Insulet stock underperforming the Dow? - MSN

Mar 28, 2026

Mar 27, 2026

Insulet Corp. stock underperforms Friday when compared to competitors - marketwatch.com

Mar 27, 2026

Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know - Yahoo Finance

Mar 27, 2026

2026-03-27 | Insulet Corporation (PODD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:PODD | Press Release - Stockhouse

Mar 27, 2026

Vanguard (PODD) parent reports 0 shares after realignment; subsidiaries to report - Stock Titan

Mar 27, 2026

Insulet (PODD) down 8.2% since last earnings report: Can it rebound? - MSN

Mar 27, 2026

Mar 26, 2026

Jayme Wilson joins Brunson, Insulet Corporation hires Cameron Yung, Ashley Csanady promoted at McMillan Vantage - iPolitics

Mar 26, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Insulet Corporation (PODD) And Encourages Investors to Connect - ACCESS Newswire

Mar 26, 2026

Insulet Trials Closed Loop Pod For Type 2 Diabetes As Shares Lag - Sahm

Mar 26, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet CorporationPODD - PR Newswire

Mar 26, 2026

PODD Investor Alert: Insulet Corp. Potential Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Executives Allegedly Misled on Safety: Levi & Korsinsky - GlobeNewswire

Mar 26, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Insulet Corporation (PODD) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Mar 26, 2026

Insulet Corporation stock hits 52-week low at $216.12 By Investing.com - Investing.com India

Mar 26, 2026

Insulet stock hits 52-week low amid Omnipod 5 defect probe and class action scrutiny - AD HOC NEWS

Mar 26, 2026

Mar 25, 2026

Published on: 2026-03-26 06:50:47 - baoquankhu1.vn

Mar 25, 2026

Insulet Corp. stock underperforms Wednesday when compared to competitors - MSN

Mar 25, 2026

Insulet (NASDAQ:PODD) Hits New 12-Month LowShould You Sell? - MarketBeat

Mar 25, 2026

Insulet stock faces securities fraud probe pressure after Omnipod 5 pod recall and sharp NASDAQ decl - AD HOC NEWS

Mar 25, 2026

Insulet slides as investors weigh Omnipod 5 device correction and potential 2026 costs - quiverquant.com

Mar 25, 2026

Insulet Corporation stock hits 52-week low at $216.12 - Investing.com

Mar 25, 2026

Is Insulet (PODD) Pricing Reflect Its Recent Share Pullback And DCF Implied Upside Potential - Sahm

Mar 25, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insulet Corporation (PODD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Mar 25, 2026

Diversified Trust Co. Purchases 6,742 Shares of Insulet Corporation $PODD - MarketBeat

Mar 25, 2026

Assenagon Asset Management S.A. Buys 24,761 Shares of Insulet Corporation $PODD - MarketBeat

Mar 25, 2026

Mar 24, 2026

Insulet stock faces pressure amid investor probe and recent share pullback on NASDAQ - AD HOC NEWS

Mar 24, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet ... - Bluefield Daily Telegraph

Mar 24, 2026

Omnipod Recall Lawsuit - AboutLawsuits.com

Mar 24, 2026

Insulet OmniPod 5 Recall Lawsuits May Be Filed Over Problems Resulting in Diabetic Ketoacidosis, Hospitalization and Death - AboutLawsuits.com

Mar 24, 2026

PODD SEC FilingsInsulet Corp 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 24, 2026

M & L Capital Management Ltd Purchases Shares of 5,630 Insulet Corporation $PODD - MarketBeat

Mar 24, 2026

PODD Stock Price, Quote & Chart | INSULET CORP (NASDAQ:PODD) - ChartMill

Mar 24, 2026